DE69825605D1 - Behandlung der schizophrenie und der psychose - Google Patents

Behandlung der schizophrenie und der psychose

Info

Publication number
DE69825605D1
DE69825605D1 DE69825605T DE69825605T DE69825605D1 DE 69825605 D1 DE69825605 D1 DE 69825605D1 DE 69825605 T DE69825605 T DE 69825605T DE 69825605 T DE69825605 T DE 69825605T DE 69825605 D1 DE69825605 D1 DE 69825605D1
Authority
DE
Germany
Prior art keywords
psychosis
treating schizophrenia
diseases
schizophrenia
methylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825605T
Other languages
English (en)
Other versions
DE69825605T2 (de
Inventor
Frank Sams-Dodd
Arnt Jorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE69825605D1 publication Critical patent/DE69825605D1/de
Application granted granted Critical
Publication of DE69825605T2 publication Critical patent/DE69825605T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69825605T 1997-05-29 1998-05-28 Behandlung der schizophrenie und der psychose Expired - Fee Related DE69825605T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK62097 1997-05-29
DK62097 1997-05-29
PCT/DK1998/000220 WO1998053820A1 (en) 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis

Publications (2)

Publication Number Publication Date
DE69825605D1 true DE69825605D1 (de) 2004-09-16
DE69825605T2 DE69825605T2 (de) 2005-09-15

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825605T Expired - Fee Related DE69825605T2 (de) 1997-05-29 1998-05-28 Behandlung der schizophrenie und der psychose

Country Status (10)

Country Link
US (1) US6297262B1 (de)
EP (1) EP1014974B1 (de)
JP (1) JP2002500651A (de)
AT (1) ATE273007T1 (de)
AU (1) AU7639598A (de)
DE (1) DE69825605T2 (de)
ES (1) ES2227836T3 (de)
PT (1) PT1014974E (de)
WO (1) WO1998053820A1 (de)
ZA (1) ZA984633B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2854836B1 (de) 2012-06-05 2018-04-04 The Board of Trustees of The Leland Stanford Junior University Ncam-peptidmimetika zur behandlung von depression
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3789039T2 (de) 1986-06-27 1994-06-09 Beecham Group Plc Verbrückte bicyclische N-heterocyclische Verbindungen.
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
KR100272614B1 (ko) 1992-08-31 2000-11-15 엠. 잭 오해니언 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체
EP0915090A1 (de) 1992-09-10 1999-05-12 Eli Lilly And Company Thiazolidinone Derivate als hypoglykämisches Mittel und für die Behandlung der Alzheimer Krankheit
HU221729B1 (hu) * 1993-08-19 2002-12-28 Novo Nordisk A/S Tiadiazolil-piridin-származékok alkalmazása antipszichotikus gyógyszerek előállítására
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Also Published As

Publication number Publication date
JP2002500651A (ja) 2002-01-08
WO1998053820A1 (en) 1998-12-03
EP1014974A1 (de) 2000-07-05
PT1014974E (pt) 2004-12-31
ATE273007T1 (de) 2004-08-15
US6297262B1 (en) 2001-10-02
EP1014974B1 (de) 2004-08-11
AU7639598A (en) 1998-12-30
DE69825605T2 (de) 2005-09-15
ZA984633B (en) 1998-12-11
ES2227836T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
DE69825605D1 (de) Behandlung der schizophrenie und der psychose
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
ATE143263T1 (de) Behandlung von neurodegenerativen erkrankungen
NO913765D0 (no) Fremgangsmaate for kontinuerlig fremstilling av tyggegummi.
NO995221D0 (no) Sulfonamider for behandling av endotelinmedierte sykdommer
NO981911D0 (no) Anvendelse av rhodaninderivater for fremstilling av et medikament for behandling av Alzheimer's sykdom
DE69919580D1 (de) Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen
NO910395L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 4-isoxazolcarboxamidderivater.
FI954119A0 (fi) Menetelmä kiinteän jätteen käsittelemiseksi
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
DE69024744D1 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
HUP0002836A2 (hu) Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
PT874843E (pt) 4-(1h-benzimidazol-2-il)¬1,4|diazepinos substituidos uteis para o tratamento de doencas alergicas
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
NO985558D0 (no) Ny forbedret formulering for behandling av tromboembolisme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee